Literature DB >> 20570399

Automated MRI measures predict progression to Alzheimer's disease.

Rahul S Desikan1, Howard J Cabral, Fabio Settecase, Christopher P Hess, William P Dillon, Christine M Glastonbury, Michael W Weiner, Nicholas J Schmansky, David H Salat, Bruce Fischl.   

Abstract

The prediction of individuals with mild cognitive impairment (MCI) destined to develop Alzheimer's disease (AD) is of increasing clinical importance. In this study, using baseline T1-weighted MRI scans of 324 MCI individuals from two cohorts and automated software tools, we employed factor analyses and Cox proportional hazards models to identify a set of neuroanatomic measures that best predicted the time to progress from MCI to AD. For comparison, cerebrospinal fluid (CSF) assessments of cellular pathology and positron emission tomography (PET) measures of metabolic activity were additionally examined. By 3 years follow-up, 60 MCI individuals from the first cohort and 58 MCI individuals from the second cohort had progressed to a diagnosis of AD. Cox models on the first cohort demonstrated significant effects for the medial temporal factor [Hazards Ratio (HR) = 0.43{95% confidence interval (CI), 0.32-0.55}, p < 0.0001], the fronto-parietoccipital factor [HR = 0.59{95% CI, 0.48-0.80}, p < 0.001], and the lateral temporal factor [HR = 0.67 {95% CI, 0.52-0.87}, p < 0.01]. When applied to the second cohort, these Cox models showed significant effects for the medial temporal factor [HR = 0.44 {0.32-0.61}, p < 0.001] and lateral temporal factor [HR = 0.49 {0.38-0.62}, p < 0.001]. In a combined Cox model, consisting of individual CSF, PET, and MRI measures that best predicted disease progression, only the medial temporal factor [HR = 0.53 {95% CI, 0.34-0.81}, p < 0.001] demonstrated a significant effect. These findings illustrate that automated MRI measures of the medial temporal cortex accurately and reliably predict time to disease progression, outperform cellular and metabolic measures as predictors of clinical decline, and can potentially serve as a predictive marker for AD. Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20570399      PMCID: PMC2902697          DOI: 10.1016/j.neurobiolaging.2010.04.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  44 in total

1.  Multimodal imaging in mild cognitive impairment: Metabolism, morphometry and diffusion of the temporal-parietal memory network.

Authors:  K B Walhovd; A M Fjell; I Amlien; R Grambaite; V Stenset; A Bjørnerud; I Reinvang; L Gjerstad; T Cappelen; P Due-Tønnessen; T Fladby
Journal:  Neuroimage       Date:  2008-11-13       Impact factor: 6.556

2.  Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI.

Authors:  Chandan Misra; Yong Fan; Christos Davatzikos
Journal:  Neuroimage       Date:  2008-11-05       Impact factor: 6.556

3.  Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.

Authors:  Randy L Buckner; Jorge Sepulcre; Tanveer Talukdar; Fenna M Krienen; Hesheng Liu; Trey Hedden; Jessica R Andrews-Hanna; Reisa A Sperling; Keith A Johnson
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

4.  Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Authors:  D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

5.  Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease.

Authors:  G Karas; J Sluimer; R Goekoop; W van der Flier; S A R B Rombouts; H Vrenken; P Scheltens; N Fox; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-22       Impact factor: 3.825

6.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.

Authors:  J L Whitwell; M M Shiung; S A Przybelski; S D Weigand; D S Knopman; B F Boeve; R C Petersen; C R Jack
Journal:  Neurology       Date:  2007-09-26       Impact factor: 9.910

7.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.

Authors:  Jennifer L Whitwell; Scott A Przybelski; Stephen D Weigand; David S Knopman; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2007-05-28       Impact factor: 13.501

8.  Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Authors:  A S Fleisher; S Sun; C Taylor; C P Ward; A C Gamst; R C Petersen; C R Jack; P S Aisen; L J Thal
Journal:  Neurology       Date:  2008-01-15       Impact factor: 9.910

9.  Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis.

Authors:  Y Yuan; Z-X Gu; W-S Wei
Journal:  AJNR Am J Neuroradiol       Date:  2008-11-11       Impact factor: 3.825

10.  Feasibility of multi-site clinical structural neuroimaging studies of aging using legacy data.

Authors:  Christine Fennema-Notestine; Anthony C Gamst; Brian T Quinn; Jenni Pacheco; Terry L Jernigan; Leon Thal; Randy Buckner; Ron Killiany; Deborah Blacker; Anders M Dale; Bruce Fischl; Brad Dickerson; Randy L Gollub
Journal:  Neuroinformatics       Date:  2007-11-13
View more
  46 in total

Review 1.  Episodic memory on the path to Alzheimer's disease.

Authors:  Michela Gallagher; Ming Teng Koh
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

Review 2.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

Review 3.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

4.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 5.  Medial temporal cortices in ex vivo magnetic resonance imaging.

Authors:  Jean C Augustinack; André J W van der Kouwe; Bruce Fischl
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

6.  Quantitative markers for neuropsychiatric disease: give it a rest.

Authors:  Bruce R Rosen; Vitaly Napadow
Journal:  Radiology       Date:  2011-04       Impact factor: 11.105

7.  Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala.

Authors:  Christian Wachinger; David H Salat; Michael Weiner; Martin Reuter
Journal:  Brain       Date:  2016-10-10       Impact factor: 13.501

Review 8.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

9.  Blood-based protein biomarkers for diagnosis of Alzheimer disease.

Authors:  James D Doecke; Simon M Laws; Noel G Faux; William Wilson; Samantha C Burnham; Chiou-Peng Lam; Alinda Mondal; Justin Bedo; Ashley I Bush; Belinda Brown; Karl De Ruyck; Kathryn A Ellis; Christopher Fowler; Veer B Gupta; Richard Head; S Lance Macaulay; Kelly Pertile; Christopher C Rowe; Alan Rembach; Mark Rodrigues; Rebecca Rumble; Cassandra Szoeke; Kevin Taddei; Tania Taddei; Brett Trounson; David Ames; Colin L Masters; Ralph N Martins
Journal:  Arch Neurol       Date:  2012-10

Review 10.  FreeSurfer.

Authors:  Bruce Fischl
Journal:  Neuroimage       Date:  2012-01-10       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.